tradingkey.logo
tradingkey.logo
Search

Cipla Expands U.S. Respiratory Portfolio With Approval Of Nintedanib Capsules (100Mg & 150Mg) For Idiopathic Pulmonary Fibrosis

ReutersApr 3, 2026 3:12 AM

- Cipla Ltd CIPL.NS:

  • CIPLA EXPANDS U.S. RESPIRATORY PORTFOLIO WITH APPROVAL OF NINTEDANIB CAPSULES (100MG & 150MG) FOR IDIOPATHIC PULMONARY FIBROSIS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI